{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:26:26Z","timestamp":1788830786180,"version":"build-2803163510"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.pmr.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T11:12:47Z","timestamp":1748085167000},"page":"531-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Guidelines and Rehabilitation in Spinal Muscular Atrophy and Duchenne\u2019s Muscular Dystrophy"],"prefix":"10.1016","volume":"36","author":[{"given":"Eleni","family":"Drakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie D.","family":"Delfiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pmr.2025.03.001_bib1","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s13311-023-01423-y","article-title":"Evolving therapeutic options for the treatment of duchenne muscular dystrophy","volume":"20","author":"D'Ambrosio","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48982-w","article-title":"Mutational spectrum and phenotypic variability of Duchenne muscular dystrophy and related disorders in a Bangladeshi population","volume":"13","author":"Sarker","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pmr.2025.03.001_bib5","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","author":"Mendell","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib6","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/mus.28255","article-title":"The impact of genotype on age at loss of ambulation in individuals with Duchenne muscular dystrophy treated with corticosteroids: a single-center study of 555 patients","volume":"70","author":"Zygmunt","year":"2024","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.pmr.2025.03.001_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103186","article-title":"Duchenne dilated cardiomyopathy: cardiac management from prevention to advanced cardiovascular therapies","volume":"9","author":"Adorisio","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.pmr.2025.03.001_bib8","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/acn3.51914","article-title":"Association between neurodevelopmental impairments and motor function in Duchenne muscular dystrophy","volume":"10","author":"Thangarajh","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"10119","key":"10.1016\/j.pmr.2025.03.001_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3233\/JND-210776","article-title":"Comparing deflazacort and prednisone in duchenne muscular dystrophy","volume":"9","author":"Biggar","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.pmr.2025.03.001_bib13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3233\/JND-230161","article-title":"Considering the promise of vamorolone for treating duchenne muscular dystrophy","volume":"10","author":"Grounds","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"10","key":"10.1016\/j.pmr.2025.03.001_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0960-8966(02)00180-3","article-title":"High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy","volume":"12","author":"Connolly","year":"2002","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pmr.2025.03.001_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with duchenne muscular dystrophy amenable to exon 51 Skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-term safety and efficacy data of golodirsen in ambulatory patients with duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Therapeut"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and safety of viltolarsen in boys with duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study","volume":"10","author":"Clemens","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.pmr.2025.03.001_bib21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040912","article-title":"Casimersen (AMONDYS 45\u2122): an antisense oligonucleotide for duchenne muscular dystrophy","volume":"12","author":"Assefa","year":"2024","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.pmr.2025.03.001_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"},{"issue":"10101","key":"10.1016\/j.pmr.2025.03.001_bib24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pmr.2025.03.001_bib25","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s00415-023-11687-1","article-title":"Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis","volume":"270","author":"Mercuri","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.pmr.2025.03.001_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical considerations for delandistrogene moxeparvovec gene therapy in patients with duchenne muscular dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 Years) with duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pmr.2025.03.001_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"1709","key":"10.1016\/j.pmr.2025.03.001_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.58347\/tml.2024.1709e","article-title":"In brief: expanded indication for Elevidys","volume":"66","year":"2024","journal-title":"Med Lett Drugs Ther"},{"issue":"14","key":"10.1016\/j.pmr.2025.03.001_bib30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3233\/JND-230185","article-title":"Management of select adverse events following delandistrogene moxeparvovec gene therapy for patients with duchenne muscular dystrophy","volume":"11","author":"Zaidman","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ppul.25175","article-title":"Cardiac medication management in Duchenne muscular dystrophy","volume":"56","author":"Wittekind","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 2","key":"10.1016\/j.pmr.2025.03.001_bib35","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1542\/peds.2018-0333I","article-title":"Cardiac management of the patient with duchenne muscular dystrophy","volume":"142","author":"Buddhe","year":"2018","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.pmr.2025.03.001_bib36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.nmd.2023.10.008","article-title":"A systematic literature review and meta-analysis of the effectiveness of vitamin D supplementation for patients with Duchenne muscular dystrophy","volume":"33","author":"Guo","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.pmr.2025.03.001_bib37","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.pmr.2025.03.001_bib38","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.nmd.2021.07.015","article-title":"Clinical outcome assessments in Duchenne muscular dystrophy and spinal muscular atrophy: past, present and future","volume":"31","author":"Nelson","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib39","first-page":"72","article-title":"Management of motor rehabilitation in individuals with muscular dystrophies. 1(st) consensus conference report from UILDM - Italian muscular dystrophy association (rome, January 25-26, 2019)","volume":"40","author":"Lombardo","year":"2021","journal-title":"Acta Myol"},{"key":"10.1016\/j.pmr.2025.03.001_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.947749","article-title":"The new challenge of \u201cexercise + X\u201d therapy for Duchenne muscular dystrophy-Individualized identification of exercise tolerance and precise implementation of exercise intervention","volume":"13","author":"Su","year":"2022","journal-title":"Front Physiol"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib41","first-page":"442","article-title":"Effectiveness of conservative non-pharmacological interventions in people with muscular dystrophies: a systematic review and meta-analysis","volume":"95","author":"Leone","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.pmr.2025.03.001_bib42","doi-asserted-by":"crossref","DOI":"10.2196\/21576","article-title":"The use of virtual reality technologies in the treatment of Duchenne muscular dystrophy: systematic review","volume":"8","author":"Baeza-Barrag\u00e1n","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3233\/JND-230055","article-title":"Age related burden of swallowing in adult patients affected by duchenne muscular dystrophy","volume":"10","author":"Crescimanno","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mus.27970","article-title":"Factors influencing the decision to introduce alternative nutrition in patients with Duchenne muscular dystrophy","volume":"68","author":"Yamamoto","year":"2023","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00455-021-10392-3","article-title":"European survey: dysphagia management in patients with neuromuscular diseases","volume":"37","author":"Audag","year":"2022","journal-title":"Dysphagia"},{"issue":"20","key":"10.1016\/j.pmr.2025.03.001_bib46","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3109\/09638288.2015.1111434","article-title":"Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management","volume":"38","author":"Toussaint","year":"2016","journal-title":"Disabil Rehabil"},{"issue":"9","key":"10.1016\/j.pmr.2025.03.001_bib47","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.nmd.2020.08.357","article-title":"249th ENMC International Workshop: the role of brain dystrophin in muscular dystrophy: Implications for clinical care and translational research, Hoofddorp, The Netherlands, November 29th-December 1st 2019","volume":"30","author":"Hendriksen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JND-240012","article-title":"Development and pilot validation of the DuMAND checklist to screen for duchenne muscular dystrophy-associated neurobehavioral difficulties (DuMAND)","volume":"11","author":"Geuens","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib49","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3233\/JND-230251","article-title":"Duchenne muscular dystrophy-associated neurobehavioral difficulties: insights from clinical practice","volume":"11","author":"Geuens","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"Suppl 2","key":"10.1016\/j.pmr.2025.03.001_bib50","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1542\/peds.2018-0333D","article-title":"Rehabilitation management of the patient with duchenne muscular dystrophy","volume":"142","author":"Case","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/mus.26727","article-title":"Ankle bracing practices in ambulatory, corticosteroid-naive boys with Duchenne muscular dystrophy","volume":"61","author":"Kern","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pmr.2025.03.001_bib52","doi-asserted-by":"crossref","DOI":"10.2490\/prm.20230038","article-title":"Long-term observation in patients with duchenne muscular dystrophy with early introduction of a standing program using knee-ankle-foot orthoses","volume":"8","author":"Fujimoto","year":"2023","journal-title":"Prog Rehabil Med"},{"issue":"15","key":"10.1016\/j.pmr.2025.03.001_bib53","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1080\/09638288.2023.2251393","article-title":"Intervention with hand orthosis: experience from boys with Duchenne muscular dystrophy and their parents","volume":"46","author":"Eriksson","year":"2024","journal-title":"Disabil Rehabil"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.pmr.2025.03.001_bib55","article-title":"Assisted standing for Duchenne muscular dystrophy","volume":"10","author":"Pedlow","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib56","first-page":"553","article-title":"Use of supported standing in males with Duchenne muscular dystrophy: individual and family perspectives","volume":"16","author":"Bonarrigo","year":"2023","journal-title":"J Pediatr Rehabil Med"},{"issue":"10","key":"10.1016\/j.pmr.2025.03.001_bib57","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1080\/09638288.2020.1810786","article-title":"The development of a consensus statement for the prescription of powered wheelchair standing devices in Duchenne muscular dystrophy","volume":"44","author":"Schofield","year":"2022","journal-title":"Disabil Rehabil"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00264-010-0957-0","article-title":"Surgical management of severe scoliosis with high risk pulmonary dysfunction in Duchenne muscular dystrophy: patient function, quality of life and satisfaction","volume":"34","author":"Takaso","year":"2010","journal-title":"Int Orthop"},{"issue":"9","key":"10.1016\/j.pmr.2025.03.001_bib59","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","article-title":"Newborn screening and birth prevalence for spinal muscular atrophy in the US","volume":"178","author":"Belter","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib60","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41436-020-0754-0","article-title":"Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data","volume":"22","author":"Chen","year":"2020","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","article-title":"Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy","volume":"28","author":"De Sanctis","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pmr.2025.03.001_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","article-title":"Spinal muscular atrophy: a clinical and research update","volume":"46","author":"Markowitz","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10.1016\/j.pmr.2025.03.001_bib65","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.braindev.2005.02.009","article-title":"Autonomic dysfunction in cases of spinal muscular atrophy type 1 with long survival","volume":"27","author":"Hachiya","year":"2005","journal-title":"Brain Dev"},{"issue":"11","key":"10.1016\/j.pmr.2025.03.001_bib66","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.3390\/ijms22115913","article-title":"Metabolic dysfunction in spinal muscular atrophy","volume":"22","author":"Deguise","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40120-024-00626-5","article-title":"Male reproduction in spinal muscular atrophy (SMA) and the potential impact of oral survival of motor neuron 2 (SMN2) pre-mRNA splicing modifiers","volume":"13","author":"Bar-Chama","year":"2024","journal-title":"Neurol Ther"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.pmr.2025.03.001_bib70","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1212\/NXG.0000000000000530","article-title":"Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy","volume":"6","author":"Cusc\u00f3","year":"2020","journal-title":"Neurol Genet"},{"key":"10.1016\/j.pmr.2025.03.001_bib71","unstructured":"Spinraza (Nusinersen): Prescribing Information: US Food and Drug Administration; 2016. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209531s011lbl.pdf. (Revised 2020, Revised 2023)."},{"key":"10.1016\/j.pmr.2025.03.001_bib72","unstructured":"Zolgensma (Onasemnogene Abeparvovec-Zioi): Prescribing Information. US Food and Drug Administration; 2019. Available at: https:\/\/www.fda.gov\/media\/126109\/download. (Revised 2023)."},{"key":"10.1016\/j.pmr.2025.03.001_bib73","unstructured":"Zolgensma (Onasemnogene Abeparvovec-Zioi): Product Information. European Medicines Agency; 2020. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma. (Revised 2024)."},{"key":"10.1016\/j.pmr.2025.03.001_bib74","unstructured":"Evrysdi (Risdiplam): Prescribing Information. US Food and Drug Administration; 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf. (Revised 2022, Revised 2023)."},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib75","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JND-221667","article-title":"DEVOTE study exploring higher dose of nusinersen in spinal muscular atrophy: study design and part a results","volume":"10","author":"Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase i ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"2 Pt 1","key":"10.1016\/j.pmr.2025.03.001_bib77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","article-title":"Optimality score for the neurologic examination of the infant at 12 and 18 months of age","volume":"135","author":"Haataja","year":"1999","journal-title":"J Pediatr"},{"issue":"9\u201310","key":"10.1016\/j.pmr.2025.03.001_bib78","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith functional motor scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The children\u2019s hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.pmr.2025.03.001_bib80","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Muscle study group and the pediatric neuromuscular clinical research network. six-minute walk test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pmr.2025.03.001_bib81","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.pmr.2025.03.001_bib82","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00415-015-7836-y","article-title":"Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS)","volume":"262","author":"Wada","year":"2015","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JND-200614","article-title":"Oral and swallowing abilities tool (OrSAT) for type 1 SMA patients: development of a new module","volume":"8","author":"Berti","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/17483107.2010.525292","article-title":"Use of orthoses and orthopaedic technical devices in proximal spinal muscular atrophy. Results of survey in 194 SMA patients","volume":"6","author":"Fujak","year":"2011","journal-title":"Disabil Rehabil Assist Technol"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5535\/arm.240046","article-title":"Rehabilitation strategies for patients with spinal muscular atrophy in the era of disease-modifying therapy","volume":"48","author":"Shin","year":"2024","journal-title":"Ann Rehabil Med"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib87","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.nmd.2021.02.011","article-title":"Filling the gaps in knowledge translation: physical therapy recommendations for individuals with spinal muscular atrophy compared to standard of care guidelines","volume":"31","author":"Trenkle","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PEP.0000000000000713","article-title":"Project Cure SMA investigator\u2019s network. stander use in spinal muscular atrophy: results from a large natural history database","volume":"32","author":"Townsend","year":"2020","journal-title":"Pediatr Phys Ther"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib89","doi-asserted-by":"crossref","DOI":"10.5014\/ajot.2020.030825","article-title":"Improving temporomandibular range of motion in people with duchenne muscular dystrophy and spinal muscular atrophy","volume":"74","author":"Lloyd Morris","year":"2020","journal-title":"Am J Occup Ther"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib90","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/BPO.0000000000002595","article-title":"Hip displacement in spinal muscular atrophy: the influences of genetic severity, functional level, and disease-modifying treatments","volume":"44","author":"Ulusaloglu","year":"2024","journal-title":"J Pediatr Orthop"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib91","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1469-8749.1987.tb02139.x","article-title":"Promotion of ambulation of patients with spinal muscular atrophy by early fitting of knee-ankle-foot orthoses","volume":"29","author":"Granata","year":"1987","journal-title":"Dev Med Child Neurol"},{"issue":"9630","key":"10.1016\/j.pmr.2025.03.001_bib92","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pmr.2025.03.001_bib93","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol"},{"issue":"21","key":"10.1016\/j.pmr.2025.03.001_bib94","doi-asserted-by":"crossref","first-page":"e2103","DOI":"10.1212\/WNL.0000000000207878","article-title":"Systematic literature review of the natural history of spinal muscular atrophy: motor function, scoliosis, and contractures","volume":"101","author":"Aponte Ribero","year":"2023","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.pmr.2025.03.001_bib95","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00586-022-07182-2","article-title":"The effect of scoliosis surgery on pulmonary function in spinal muscular atrophy patients: review of the literature and a meta-analysis","volume":"31","author":"Angeli","year":"2022","journal-title":"Eur Spine J"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib96","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1469-8749.1989.tb04029.x","article-title":"Scoliosis in spinal muscular atrophy: natural history and management","volume":"31","author":"Merlini","year":"1989","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.pmr.2025.03.001_bib97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1748-7161-3-14","article-title":"A Dutch guideline for the treatment of scoliosis in neuromuscular disorders","volume":"3","author":"Mullender","year":"2008","journal-title":"Scoliosis"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib98","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1212\/WNL.0000000000007742","article-title":"Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy","volume":"93","author":"Wijngaarde","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pmr.2025.03.001_bib99","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/children10060998","article-title":"Early development of spinal deformities in children severely affected with spinal muscular atrophy after gene therapy with onasemnogene abeparvovec-preliminary results","volume":"10","author":"Soini","year":"2023","journal-title":"Children"},{"issue":"1","key":"10.1016\/j.pmr.2025.03.001_bib100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/18632521231214780","article-title":"Safety and efficacy of growth-friendly instrumentation for early-onset scoliosis in patients with spinal muscular atrophy type 1 in the disease-modifying treatment era","volume":"18","author":"Cetik","year":"2023","journal-title":"J Child Orthop"},{"issue":"4","key":"10.1016\/j.pmr.2025.03.001_bib101","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/CPJ.0000000000001179","article-title":"Scoliosis in spinal muscular atrophy type 1 in the nusinersen era","volume":"12","author":"Al Amrani","year":"2022","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"10.1016\/j.pmr.2025.03.001_bib102","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JND-230077","article-title":"Treatment of symptomatic spinal muscular atrophy with nusinersen: a prospective longitudinal study on scoliosis progression","volume":"11","author":"Ip","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib103","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/18632521241235028","article-title":"Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: what about spine and hip?","volume":"18","author":"Yasar","year":"2024","journal-title":"J Child Orthop"},{"key":"10.1016\/j.pmr.2025.03.001_bib104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejpn.2023.11.006","article-title":"The emerging spectrum of neurodevelopmental comorbidities in early-onset Spinal Muscular Atrophy","volume":"48","author":"Baranello","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"issue":"supplement 2","key":"10.1016\/j.pmr.2025.03.001_bib105","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.nmd.2023.07.095","article-title":"P213 beneath the iceberg: spinal muscular atrophy (SMA) and autistic spectrum disorder","volume":"33","author":"Al\u0131c\u0131","year":"2023","journal-title":"Neuromuscular Dis"},{"issue":"13","key":"10.1016\/j.pmr.2025.03.001_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33677","article-title":"Cognition and communication in patients with spinal muscular atrophy: a systematic review","volume":"10","author":"Akodad","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.pmr.2025.03.001_bib107","series-title":"Autism spectrum disorders [Internet]","article-title":"Autism spectrum disorders: etiology and pathology","author":"Sauer","year":"2021"},{"issue":"6","key":"10.1016\/j.pmr.2025.03.001_bib108","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202401145","article-title":"Presynaptic perspective: axonal transport defects in neurodevelopmental disorders","volume":"223","author":"Xiong","year":"2024","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.pmr.2025.03.001_bib109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.jnen.0000205144.54457.a3","article-title":"Neuronal-specific roles of the survival motor neuron protein: evidence from survival motor neuron expression patterns in the developing human central nervous system","volume":"65","author":"Giavazzi","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pmr.2025.03.001_bib110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpn.2024.05.002","article-title":"Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life","volume":"51","author":"Steffens","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.pmr.2025.03.001_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1326528","article-title":"Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study","volume":"15","author":"Bitetti","year":"2024","journal-title":"Front Neurol"}],"container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965125000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965125000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:38:11Z","timestamp":1750981091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047965125000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1047965125000221"],"URL":"https:\/\/doi.org\/10.1016\/j.pmr.2025.03.001","relation":{},"ISSN":["1047-9651"],"issn-type":[{"value":"1047-9651","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Guidelines and Rehabilitation in Spinal Muscular Atrophy and Duchenne\u2019s Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Physical Medicine and Rehabilitation Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmr.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}